Ribavirin reduces clinical signs and pathological changes of experimental autoimmune encephalomyelitis in Dark Agouti rats. 2003

Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
Department of Neurobiology and Immunology, Institute for Biological Research Sinisa Stankovic, University of Belgrade, Belgrade, Yugoslavia.

The effect of ribavirin on development of experimental autoimmune encephalomyelitis (EAE) was investigated. The disease was induced in genetically susceptible Dark Agouti rats with syngeneic spinal cord homogenate in complete Freund's adjuvant (SCH-CFA). Depending on the amount of mycobacteria in CFA, the animals developed either moderate or severe EAE. Ribavirin (1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide) was applied i.p. at a daily dosage of 30 mg/kg in two treatment protocols: from the start of immunization (preventive treatment) or from the onset of the first EAE signs after the induction (therapeutic treatment). Signs of EAE began between 7 and 9 days after induction and peaked at days 11-13. In moderate EAE (mean maximal severity score 3.33 +/- 0.21), the recovery was completed by days 23-26, whereas, in severe EAE (mean maximal severity score 4.5 +/- 0.23), obvious recovery was not detected. Preventive ribavirin treatment significantly decreased clinical signs after both moderate (score 1.75 +/- 0.25, P < 0.05) and severe (score 3.62 +/- 0.31, P < 0.015) immunization. Also, disease manifestations were reduced by therapeutic treatment of ribavirin (mean maximal severity score 2.5 +/- 0.2 vs. 3.33 +/- 0.21 in controls, P < 0.005) but less so in comparison with preventive treatment. Analysis of the effects of ribavirin on histopathologic changes in the spinal cord tissue revealed a reduction of mononuclear cell infiltrates, composed of T cells and macrophages/microglia, and the absence of demyelination, which were pronounced in control EAE animals. Beneficial effects of preventive and therapeutic treatment with ribavirin on development of EAE suggest this nucleoside analogue as a useful candidate for therapy in multiple sclerosis.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008264 Macrophages The relatively long-lived phagocytic cell of mammalian tissues that are derived from blood MONOCYTES. Main types are PERITONEAL MACROPHAGES; ALVEOLAR MACROPHAGES; HISTIOCYTES; KUPFFER CELLS of the liver; and OSTEOCLASTS. They may further differentiate within chronic inflammatory lesions to EPITHELIOID CELLS or may fuse to form FOREIGN BODY GIANT CELLS or LANGHANS GIANT CELLS. (from The Dictionary of Cell Biology, Lackie and Dow, 3rd ed.) Bone Marrow-Derived Macrophages,Monocyte-Derived Macrophages,Macrophage,Macrophages, Monocyte-Derived,Bone Marrow Derived Macrophages,Bone Marrow-Derived Macrophage,Macrophage, Bone Marrow-Derived,Macrophage, Monocyte-Derived,Macrophages, Bone Marrow-Derived,Macrophages, Monocyte Derived,Monocyte Derived Macrophages,Monocyte-Derived Macrophage
D011919 Rats, Inbred Strains Genetically identical individuals developed from brother and sister matings which have been carried out for twenty or more generations or by parent x offspring matings carried out with certain restrictions. This also includes animals with a long history of closed colony breeding. August Rats,Inbred Rat Strains,Inbred Strain of Rat,Inbred Strain of Rats,Inbred Strains of Rats,Rat, Inbred Strain,August Rat,Inbred Rat Strain,Inbred Strain Rat,Inbred Strain Rats,Inbred Strains Rat,Inbred Strains Rats,Rat Inbred Strain,Rat Inbred Strains,Rat Strain, Inbred,Rat Strains, Inbred,Rat, August,Rat, Inbred Strains,Rats Inbred Strain,Rats Inbred Strains,Rats, August,Rats, Inbred Strain,Strain Rat, Inbred,Strain Rats, Inbred,Strain, Inbred Rat,Strains, Inbred Rat
D003711 Demyelinating Diseases Diseases characterized by loss or dysfunction of myelin in the central or peripheral nervous system. Clinically Isolated CNS Demyelinating Syndrome,Clinically Isolated Syndrome, CNS Demyelinating,Demyelinating Disorders,Demyelination,Demyelinating Disease,Demyelinating Disorder,Demyelinations
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004198 Disease Susceptibility A constitution or condition of the body which makes the tissues react in special ways to certain extrinsic stimuli and thus tends to make the individual more than usually susceptible to certain diseases. Diathesis,Susceptibility, Disease,Diatheses,Disease Susceptibilities,Susceptibilities, Disease
D004681 Encephalomyelitis, Autoimmune, Experimental An experimental animal model for central nervous system demyelinating disease. Inoculation with a white matter emulsion combined with FREUND'S ADJUVANT, myelin basic protein, or purified central myelin triggers a T cell-mediated immune response directed towards central myelin. The pathologic features are similar to MULTIPLE SCLEROSIS, including perivascular and periventricular foci of inflammation and demyelination. Subpial demyelination underlying meningeal infiltrations also occurs, which is also a feature of ENCEPHALOMYELITIS, ACUTE DISSEMINATED. Passive immunization with T-cells from an afflicted animal to a normal animal also induces this condition. (From Immunol Res 1998;17(1-2):217-27; Raine CS, Textbook of Neuropathology, 2nd ed, p604-5) Autoimmune Encephalomyelitis, Experimental,Encephalomyelitis, Allergic,Encephalomyelitis, Experimental Autoimmune,Allergic Encephalomyelitis,Allergic Encephalomyelitis, Experimental,Autoimmune Experimental Encephalomyelitis,Experimental Allergic Encephalomyelitis,Experimental Autoimmune Encephalomyelitis,Encephalomyelitis, Autoimmune Experimental,Encephalomyelitis, Experimental Allergic,Experimental Allergic Encephalomyelitides,Experimental Encephalomyelitis, Autoimmune
D005260 Female Females
D000276 Adjuvants, Immunologic Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity. Immunoactivators,Immunoadjuvant,Immunoadjuvants,Immunologic Adjuvant,Immunopotentiator,Immunopotentiators,Immunostimulant,Immunostimulants,Adjuvant, Immunologic,Adjuvants, Immunological,Immunologic Adjuvants,Immunological Adjuvant,Adjuvant, Immunological,Immunological Adjuvants
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia

Related Publications

Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
January 2015, Journal of neuroimmunology,
Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
April 2004, Clinical and experimental immunology,
Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
April 2015, British journal of pharmacology,
Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
January 2013, Frontiers in neurology,
Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
January 2009, Journal of neurology,
Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
March 2024, Immunology letters,
Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
June 2010, Parasite immunology,
Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
April 2012, Journal of neuroimmunology,
Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
June 2021, Experimental parasitology,
Irena Milicevic, and Sanja Pekovic, and Sanja Subasic, and Marija Mostarica-Stojkovic, and Stanislava Stosic-Grujicic, and Ljubica Medic-Mijacevic, and Vjera Pejanovic, and Ljubisav Rakic, and Mirjana Stojiljkovic
December 2008, Neuroscience letters,
Copied contents to your clipboard!